Promising drug cocktail aims to eradicate hidden breast cancer cells

NCT ID NCT04434040

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, sacituzumab govitecan and atezolizumab, can clear leftover cancer cells in the breast or lymph nodes of people with triple negative breast cancer. About 40 participants who still have cancer after standard chemotherapy will receive the combination. The main goal is to see if the drugs can make cancer DNA disappear from the blood, which may lower the risk of the cancer returning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Neoplasm, Residual triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CIRCULATING TUMOR DNA RESIDUAL CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94115, United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
WITHDRAWN

New Lenox, Illinois, 60451, United States
University of Chicago Medical Center
WITHDRAWN

Chicago, Illinois, 60637, United States
University of Chicago Medical Center for Advanced Care Orland Park
WITHDRAWN

Orland Park, Illinois, 60462, United States
University of Pennsylvania-Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.